Seattle-based Synthesize Bio, a biotechnology company, secured a $10 million seed funding round. Madrona led the investment, with participation from Sahsen Ventures, Inner Loop Capital, Point Field Partners, and AI2 Incubator. This capital will accelerate the development of Synthesize Bio's generative genomics models, expanding access for biopharmaceutical companies and researchers.
Synthesize Bio pioneers biological foundation models. These models simulate gene expression experiments. Its Generate Expression Model-1 (GEM-1) predicts experimental outcomes with high accuracy. The model was trained on a deeply curated RNA-seq dataset.
Advancing AI in Drug Discovery
GEM-1 generates in silico data matching wet lab experiments. This capability establishes a new paradigm for generative AI in biology. The company actively engages biopharma partners to enable confident drug discovery decisions. Furthermore, GEM-1 helps de-risk clinical pipelines.
The platform offers a powerful tool for researchers. It accelerates applications relying on gene expression data.
GEM-1 is now available via API clients. Other companies like Insitro and Recursion Pharmaceuticals also leverage machine learning for biological insights.